SAN DIEGO, CA, May 09, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nascent Biotech, Inc. (OTCQB: NBIO) founder Dr. Mark C. Glassy will present an abstract on a natural human lgG1 mAb, Pritumumab, which targets cell surface expressed vimentin and inhibits tumor growth, at the AAI convention this week in San Diego, California.
Nascent CEO Sean Carrick stated, “We are pleased Dr. Glassy will be presenting the abstract, a collaboration of numerous individuals involved in the project.”
Founder Mark Glassy added, “I am looking forward to discussing the abstract with the more than 15,000 attendees expected at the conference.”
Click here to download the abstract in PDF format.
About Nascent Biotech, Inc.: Nascent Biotech, Inc. is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers with an Investigational New Drug (IND) application cleared by the FDA for Phase 1 clinical trials. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Safe Harbor: Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc's Form 10, filed on October 28, 2014, and subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Contact Information:
Nascent Biotech, Inc.
Sean Carrick
President |CEO
772.713.0541
sean.carrick@nascentbiotech.com